Phaseline

Companies › Rapamycin Holdings

Rapamycin Holdings: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jul 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sirolimus
FK506-binding protein 1A inhibitor
FKBP1APhase 3Familial Adenomatous Polyposis (FAP); Familial Adenomatous PolyposisJul 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04230499SirolimusPhase 2Familial Adenomatous PolyposisOncologyDec 2024
NCT06950385SirolimusPhase 3Familial Adenomatous Polyposis (FAP)OncologyJul 2030

Targets

FKBP1A (1)

Companies with the same targets

Eisai CSPC ZhongQi Pharmaceutical Technology Restorbio Novartis AgelessRx Novaliq Palvella Therapeutics Jiangsu Simcere Pharmaceutical Aadi Bioscience Eyestem Research

Companies built like this

Aadi Bioscience Mercator MedSystems Verity Pharmaceuticals SecuraBio Fidia Farmaceutici

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.